<DOC>
	<DOC>NCT02108444</DOC>
	<brief_summary>This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma patients with hepatitis B virus infection.</brief_summary>
	<brief_title>Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients</brief_title>
	<detailed_description>All eligible patients received prophylactic antiviral therapy during and within 6 months after chemotherapy in previous sudy. We did not assign specific interventions to the subjects in this study. The primary endpoint of this study is the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy. The secondary endpoints include the incidence of hepatitis flare related to hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the tumor response rate, and overall survival rate.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>treatmentnaive patients with lymphoma patients with a history of previous exposure to hepatitis B virus (HBV): HBsAg or hepatitis B core antibody (antiHBc) positive HBsAg and HBcAb negative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>hepatitis</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Hematologic Diseases</keyword>
</DOC>